Arecor Limited has dosed the first patient in a trial of its ultra-rapid acting insulin product, AT247.
The pharmaceutical firm said the double-blind, three-way cross over study in Austria will compare the results of AT247 against current insulin treatments for people living with Type 1 diabetes.
AT247 is designed to accelerate the absorption of insulin following injections, which the company says will enable diabetes patients to more effectively manage their blood glucose levels, particularly after meals.
Sarah Howell, Arecor’s chief executive, said the initiation of the trial was “an important step” in the company’s strategy to develop fast-acting insulins to improve treatments for diabetes.
“I look forward to reporting on the progress of this product candidate, the first in our proprietary product development pipeline.”